Skip to main
SPRB

SPRB Stock Forecast & Price Target

SPRB Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 17%
Buy 67%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Spruce Biosciences Inc is well-positioned to capitalize on the growing market for rare endocrine disorders, particularly with its lead product candidate TA-ERT, which has demonstrated significant efficacy in improving cognitive and communicative functions in patients with MPS IIIA. The company benefits from substantial financial backing, having secured up to $50 million from Avenue Capital, contingent on achieving key regulatory milestones, which underscores investor confidence in its development pipeline. Additionally, the successful commercialization of enzyme replacement therapies (ERTs) in similar markets suggests a strong revenue potential for TA-ERT, bolstered by its differentiated mechanism of action and favorable safety profile compared to existing therapies.

Bears say

Spruce Biosciences Inc faces significant financial challenges as it continues to incur net losses, a situation expected to persist at least until the commercialization of its product candidate, TA-ERT. The company has not yet commercialized any products and will require substantial investment to build the infrastructure necessary for a successful launch, which introduces risks of medium-term dilution. Additionally, recent FDA feedback indicates hurdles in achieving regulatory approval and the potential for underwhelming commercial success due to competitive market factors and slow uptake, further contributing to a negative financial outlook.

SPRB has been analyzed by 6 analysts, with a consensus rating of Buy. 17% of analysts recommend a Strong Buy, 67% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Spruce Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Spruce Biosciences Inc (SPRB) Forecast

Analysts have given SPRB a Buy based on their latest research and market trends.

According to 6 analysts, SPRB has a Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $177.92, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $177.92, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Spruce Biosciences Inc (SPRB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.